Table 1.
Baseline patient characteristics.
| Placebo (n = 47) | T/O (doses combined) (n = 104) | |
|---|---|---|
| Male, n (%) | 29 (61.7) | 73 (70.2) |
| Mean (SD) age, years | 61.1 (6.4) | 64.9 (7.4) |
| Pre-bronchodilator | ||
| Mean (SD) FEV1, l | 1.471 (0.434) | 1.351 (0.420) |
| Post-bronchodilator (albuterol) | ||
| Mean (SD) FEV1, l | 1.662 (0.419) | 1.564 (0.440) |
| Mean (SD) predicted normal FEV1, % | 60.4 (11.6) | 57.0 (13.4) |
| Mean (SD) FEV1 change from pre-bronchodilator, l | 0.191 (0.155) | 0.213 (0.143) |
| Mean (SD) FEV1/FVC, % | 53.2 (9.8) | 50.9 (10.8) |
| GOLD, n (%) | ||
| 2 | 37 (78.7) | 74 (71.2) |
| 3 | 10 (21.3) | 27 (26.0) |
| Mean (SD) body mass index, kg/m2 | 28.3 (5.2) | 27.6 (5.0) |
| Current smoker, n (%) | 22 (46.8) | 36 (34.6) |
| Ex-smoker, n (%) | 25 (53.2) | 68 (65.4) |
| Mean (SD) smoking history, pack-years | 45.8 (23.4) | 50.9 (28.3) |
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; SD, standard deviation; T/O, tiotropium/olodaterol.